New Data Help Size Up Novel Class Of SGLT-2 Inhibitors In Diabetes

Though probable class side effects of urinary tract and genital infections remain worrisome, SGLT-2 inhibitors nevertheless have potential as add-ons to multiple kinds of diabetes drugs, based on data released at the recent American Diabetes Association meeting

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet